logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Annexon, Inc.

ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX0ā€¦ read more

Healthcare

Biotechnology

6 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$5.10

Price

-3.32%

-$0.17

$5.27

Previous Close

$5.39

Open

Premium

52w Discount
Market Cap

$834.778m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$196.476m

-49.8%

1y CAGR

-15.8%

3y CAGR

-14.1%

5y CAGR
EPS

-$1.22

-39.6%

1y CAGR

+11.8%

3y CAGR

+14.4%

5y CAGR
Book Value

$204.533m

$262.888m

Assets

$58.355m

Liabilities

$25.434m

Debt
Debt to Assets

9.7%

-0.1x

Debt to EBITDA
Free Cash Flow

-$183.160m

-49.6%

1y CAGR

-15.2%

3y CAGR

-14.9%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.